[{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"GOG Foundation | European Network for Gynaecological Oncological Trial Groups | Australia New Zealand Gynaecological Oncology Group | Korean Gynecologic Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ GOG Foundation | European Network for Gynaecological Oncological Trial Groups | Australia New Zealand Gynaecological Oncology Group | Korean Gynecologic Oncology Group","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ GOG Foundation | European Network for Gynaecological Oncological Trial Groups | Australia New Zealand Gynaecological Oncology Group | Korean Gynecologic Oncology Group"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0.16,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Oberland Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Oberland Capital Management"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Guggenheim Securities","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Guggenheim Securities"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ RTW Investments","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ RTW Investments"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"University of Oklahoma","sponsor":"Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"University of Oklahoma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Oklahoma \/ Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"University of Oklahoma \/ Verastem Oncology"},{"orgOrder":0,"company":"Ryan H. Moy, MD, PhD","sponsor":"Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Ryan H. Moy, MD, PhD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryan H. Moy, MD, PhD \/ Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Ryan H. Moy, MD, PhD \/ Verastem Oncology"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pharmaceutical \/ Verastem Oncology"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ RBC Capital Markets","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ RBC Capital Markets"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Truist Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Truist Securities","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Truist Securities"},{"orgOrder":0,"company":"Tempus","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tempus \/ Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Tempus \/ Verastem Oncology"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Chicago \/ Verastem Oncology","highestDevelopmentStatusID":"7","companyTruncated":"University of Chicago \/ Verastem Oncology"},{"orgOrder":0,"company":"Adrienne G. Waks","sponsor":"Verastem Oncology | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adrienne G. Waks","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adrienne G. Waks \/ Verastem Oncology | Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Adrienne G. Waks \/ Verastem Oncology | Eli Lilly"},{"orgOrder":0,"company":"Institute of Cancer Research, United Kingdom","sponsor":"Minderoo Foundation | Verastem Oncology | Royal Marsden NHS Foundation Trust | Cambridge University Hospitals NHS Foundation Trust | Cancer Research UK | University of Cambridge","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institute of Cancer Research, United Kingdom","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Institute of Cancer Research, United Kingdom \/ Minderoo Foundation | Verastem Oncology | Royal Marsden NHS Foundation Trust | Cambridge University Hospitals NHS Foundation Trust | Cancer Research UK | University of Cambridge","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Cancer Research, United Kingdom \/ Minderoo Foundation | Verastem Oncology | Royal Marsden NHS Foundation Trust | Cambridge University Hospitals NHS Foundation Trust | Cancer Research UK | University of Cambridge"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Amgen Inc"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"||GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Verastem Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Verastem Oncology"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Preclinical","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"European Network for Gynaecological Oncological Trial Groups | GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ European Network for Gynaecological Oncological Trial Groups | GOG Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ European Network for Gynaecological Oncological Trial Groups | GOG Foundation"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Verastem Oncology"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Verastem Oncology"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Verastem Oncology"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Japanese Gynecologic Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Japanese Gynecologic Oncology Group","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Japanese Gynecologic Oncology Group"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Amgen Inc"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avutometinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verastem Oncology \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Avutometinib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Through the collaboration, Tempus completed testing in Verastem’s trial, which evaluated the combination of VS-6766 (avutometinib) and defactinib to treat recurrent low-grade serous ovarian cancer.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 20, 2025

                          Lead Product(s) : Avutometinib,Defactinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Verastem Oncology

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Avmapki Fakzynja Co-Pack, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with KRAS-mutated recurrent LGSOC.

                          Product Name : Avmapki Fakzynja Co-Pack

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 08, 2025

                          Lead Product(s) : Avutometinib,Defactinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : The proceeds from the financing are expected to fund the potential launch of VS-6766 (avutometinib) and defactinib in recurrent low-grade serous ovarian cancer.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 25, 2025

                          Lead Product(s) : Avutometinib,Defactinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : RTW Investments

                          Deal Size : $75.0 million

                          Deal Type : Private Placement

                          blank

                          04

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : The financing aims to advance the clinical development of company's lead product, VS-6766 (Avutometinib) plus defactinib. It is being evaluated for the KRAS mutant low-grade serous ovarian cancer.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 13, 2025

                          Lead Product(s) : Avutometinib,Defactinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Oberland Capital Management

                          Deal Size : $157.5 million

                          Deal Type : Financing

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, being development for adults with recurrent KRAS mutant low-grade serous ovarian cancer.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 30, 2024

                          Lead Product(s) : Avutometinib,Defactinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Combination of avutometinib, a RAF/MEK clamp with sotorasib & defactinib, , being developed for the treatment of KRAS G12C mutant non-small cell lung cancer.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 18, 2024

                          Lead Product(s) : Avutometinib,Defactinib,Sotorasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 12, 2024

                          Lead Product(s) : Avutometinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Japanese Gynecologic Oncology Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, being development for adults with recurrent KRAS mutant low-grade serous ovarian cancer.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 31, 2024

                          Lead Product(s) : Avutometinib,Defactinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Institute of Cancer Research, United Kingdom

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Institute of Cancer Research, United Kingdom

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Avutometinib

                          Therapeutic Area : Oncology

                          Study Phase : Phase I/ Phase II

                          Sponsor : Minderoo Foundation | Verastem Oncology | Royal Marsden NHS Foundation Trust | Cambridge University Hospitals NHS Foundation Trust | Cancer Research UK | University of Cambridge

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 08, 2024

                          Lead Product(s) : Avutometinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Minderoo Foundation | Verastem Oncology | Royal Marsden NHS Foundation Trust | Cambridge University Hospitals NHS Foundation Trust | Cancer Research UK | University of Cambridge

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, being development for adult patients with pancreatic ductal adenocarcinoma.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 29, 2024

                          Lead Product(s) : Avutometinib,Defactinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank